{"title":"重症监护病房中的耳念珠菌感染:抗真菌耐药性、死亡率和感染控制干预措施。","authors":"Semiha Solak Grassie, Nilgün Karabıçak, Tuğçe Ünalan Altıntop","doi":"10.1556/030.2025.02615","DOIUrl":null,"url":null,"abstract":"<p><p>Candida auris spreads rapidly and causes outbreaks worldwide. Strict infection control is critical to control its spread; however, it is challenging and requires a special approach. This study aims to investigate the colonization and infection of C. auris in intensive care units (ICUs), analyses its susceptibility, and mortality rates, and contributes to an effective infection control.An infection control study was planned, and a C. auris infection control bundle and checklist were developed. During the study's pre-intervention, intervention, and post-intervention periods, C. auris candidemia cases and colonized patients were identified. Until the infection control intervention, all the candidemia cases, antifungal resistance, and mortality were investigated retrospectively. Clinical isolates were identified by phenotypic and genotypic characterization using MALDI-TOF MS Biotyper (Bruker Daltonics, Bremen, Germany) and sequencing.During the pre-intervention, intervention, and post-intervention periods, 26 C. auris cases were identified. Pan-resistant C. auris isolates were 3.84%, and the multidrug resistance was 65.38%. With the infection control intervention, the number of colonized patients decreased (pre-intervention 9.61‰, intervention 6.19‰, post-intervention 5.20‰). Candidemia incidence decreased from 4.09 to 2.3‰. No new cases of candidemia were observed at the end of the study.The risk of new cases is elevated in the rooms where multiple C. auris cases have been previously isolated. Mortality rate was high; namely, 76.92% of patients died, and 19.23% of strains were resistant to anidulofungin, one of the most commonly used antifungals. Despite the short implementation period, the infection control bundle and checklist have been demonstrated to be effective in controlling C. auris spread in the ICU.</p>","PeriodicalId":7119,"journal":{"name":"Acta microbiologica et immunologica Hungarica","volume":" ","pages":""},"PeriodicalIF":1.3000,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Candida auris infections in an intensive care unit: Antifungal resistance, mortality rates and infection control interventions.\",\"authors\":\"Semiha Solak Grassie, Nilgün Karabıçak, Tuğçe Ünalan Altıntop\",\"doi\":\"10.1556/030.2025.02615\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Candida auris spreads rapidly and causes outbreaks worldwide. Strict infection control is critical to control its spread; however, it is challenging and requires a special approach. This study aims to investigate the colonization and infection of C. auris in intensive care units (ICUs), analyses its susceptibility, and mortality rates, and contributes to an effective infection control.An infection control study was planned, and a C. auris infection control bundle and checklist were developed. During the study's pre-intervention, intervention, and post-intervention periods, C. auris candidemia cases and colonized patients were identified. Until the infection control intervention, all the candidemia cases, antifungal resistance, and mortality were investigated retrospectively. Clinical isolates were identified by phenotypic and genotypic characterization using MALDI-TOF MS Biotyper (Bruker Daltonics, Bremen, Germany) and sequencing.During the pre-intervention, intervention, and post-intervention periods, 26 C. auris cases were identified. Pan-resistant C. auris isolates were 3.84%, and the multidrug resistance was 65.38%. With the infection control intervention, the number of colonized patients decreased (pre-intervention 9.61‰, intervention 6.19‰, post-intervention 5.20‰). Candidemia incidence decreased from 4.09 to 2.3‰. No new cases of candidemia were observed at the end of the study.The risk of new cases is elevated in the rooms where multiple C. auris cases have been previously isolated. Mortality rate was high; namely, 76.92% of patients died, and 19.23% of strains were resistant to anidulofungin, one of the most commonly used antifungals. Despite the short implementation period, the infection control bundle and checklist have been demonstrated to be effective in controlling C. auris spread in the ICU.</p>\",\"PeriodicalId\":7119,\"journal\":{\"name\":\"Acta microbiologica et immunologica Hungarica\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":1.3000,\"publicationDate\":\"2025-06-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Acta microbiologica et immunologica Hungarica\",\"FirstCategoryId\":\"99\",\"ListUrlMain\":\"https://doi.org/10.1556/030.2025.02615\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta microbiologica et immunologica Hungarica","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1556/030.2025.02615","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
耳念珠菌传播迅速,并在世界范围内引起疫情。严格的感染控制对控制其传播至关重要;然而,它是具有挑战性的,需要一个特殊的方法。本研究旨在了解auris在重症监护病房(icu)的定植和感染情况,分析其易感性和死亡率,为有效控制感染提供依据。计划进行感染控制研究,并制定了耳念珠菌感染控制包和检查表。在研究的干预前、干预和干预后阶段,确定了耳念珠菌病例和定植患者。在感染控制干预前,对所有念珠菌病例、抗真菌药物耐药性和死亡率进行回顾性调查。临床分离株采用MALDI-TOF MS Biotyper (Bruker Daltonics, Bremen, Germany)和测序进行表型和基因型鉴定。在干预前、干预和干预后,共发现26例耳念珠菌病例。金黄色葡萄球菌耐药率为3.84%,耐多药率为65.38%。感染控制干预后,定植患者数量下降(干预前9.61‰,干预后6.19‰,干预后5.20‰)。念珠菌发病率由4.09‰降至2.3‰。在研究结束时,没有观察到新的念珠菌病例。在以前曾隔离过多例金黄色葡萄球菌病例的房间中,新病例的风险升高。死亡率很高;76.92%的患者死亡,19.23%的菌株对最常用的抗真菌药anidulofungin耐药。尽管实施周期较短,但感染控制包和检查表已被证明在控制耳球菌在ICU的传播方面是有效的。
Candida auris infections in an intensive care unit: Antifungal resistance, mortality rates and infection control interventions.
Candida auris spreads rapidly and causes outbreaks worldwide. Strict infection control is critical to control its spread; however, it is challenging and requires a special approach. This study aims to investigate the colonization and infection of C. auris in intensive care units (ICUs), analyses its susceptibility, and mortality rates, and contributes to an effective infection control.An infection control study was planned, and a C. auris infection control bundle and checklist were developed. During the study's pre-intervention, intervention, and post-intervention periods, C. auris candidemia cases and colonized patients were identified. Until the infection control intervention, all the candidemia cases, antifungal resistance, and mortality were investigated retrospectively. Clinical isolates were identified by phenotypic and genotypic characterization using MALDI-TOF MS Biotyper (Bruker Daltonics, Bremen, Germany) and sequencing.During the pre-intervention, intervention, and post-intervention periods, 26 C. auris cases were identified. Pan-resistant C. auris isolates were 3.84%, and the multidrug resistance was 65.38%. With the infection control intervention, the number of colonized patients decreased (pre-intervention 9.61‰, intervention 6.19‰, post-intervention 5.20‰). Candidemia incidence decreased from 4.09 to 2.3‰. No new cases of candidemia were observed at the end of the study.The risk of new cases is elevated in the rooms where multiple C. auris cases have been previously isolated. Mortality rate was high; namely, 76.92% of patients died, and 19.23% of strains were resistant to anidulofungin, one of the most commonly used antifungals. Despite the short implementation period, the infection control bundle and checklist have been demonstrated to be effective in controlling C. auris spread in the ICU.
期刊介绍:
AMIH is devoted to the publication of research in all fields of medical microbiology (bacteriology, virology, parasitology, mycology); immunology of infectious diseases and study of the microbiome related to human diseases.